STAT3 and neoplasm: In a recent in vitro study in breast cancer sentinel lymph nodes (SLN), van Pul et al. showed that STAT3 inhibition in immune cells, combined with immune stimulation through TLR9 using CpG-B, could activate dendritic cell (DC) subsets in SLN cultures and increased tumor-specific T cell responses [52].